the world is changing, so are we !
DESCRIPTION
The world is changing, so are we !. Agenda. Overview: the Bio-Pharma industry Major challenges for developers Genzyme: Innovations for unmet medical needs. Overview: the Bio-Pharma industry. TOP 10 TRENDS ON THE PHARMA INDUSTRY HORIZON. 1. 6. Industry consolidation will accelerate. - PowerPoint PPT PresentationTRANSCRIPT
AgendaAgenda
• Overview: the Bio-Pharma industry
• Major challenges for developers
• Genzyme: Innovations for unmet
medical needs
Overview: the Bio-Pharma industry
TOP 10 TRENDS ON THE PHARMA INDUSTRY HORIZON
10
9
8
7
6
5
4
3
2
1• Industry consolidation
will accelerate
• Increased risk-sharing across development projects
• Continued separation of PC and specialty companies
• Increased pricing and regulatory pressures in Europe
• Slow, steady experimental re-engineering of commercial model
• Shift to more serious tone in DTC advertising
• Increasing risk-sharing to the consumer
• Increased Rx interest in Gx (generics) and other LCM(Low cost medications)
• Continued productivity
and cost transformation
• Drug safety and healthcare compliance ???
New Drug Approvals Are Not Keeping Pace with Rising R&D
Spending
New Drug Approvals Are Not Keeping Pace with Rising R&D
Spending
0
15
30
45
60
1963 1968 1973 1978 1983 1988 1993 1998 2003
NC
E A
pp
rov
als
0
20
40
R&
D E
xp
en
ditu
res
(Billio
ns
of 2
00
4$
)
Source: Tufts CSDD Approved NCE Database, PhRMA, 2005R&D expenditures are adjusted for inflation
R&D Expenditures
NCE Approvals
0
70
140
210
280
1980 1984 1988 1992 1996 2000 2004
Sa
les
(b
illio
ns
of
20
04
$)
0
10
20
30
40
R&
D (b
illion
s o
f 20
04
$)
Pharma Industry Sales are Generally Keeping Pace with R&D
Spending
Pharma Industry Sales are Generally Keeping Pace with R&D
Spending
Source: PhRMA, Tufts CSDD Analysis, 2005
R&D Expenditures
Pharma Sales
0
55
NM
E/B
LA
Ap
pro
vals
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
NME ApprovalsBLAs Approvals
Source: FDA
NME Approvals are Declining –Biologics are
Filling the Void
NME Approvals are Declining –Biologics are
Filling the Void
Growing Percentage of NME Approvals are from Small/Mid-Tier
Pharma Firms
Growing Percentage of NME Approvals are from Small/Mid-Tier
Pharma Firms
37%
63%
53%
47%
52%
48%
74%
26%
0
40
Nu
mb
er
of
NM
E A
pp
rov
als
2001 2002 2003 2004
Small/Mid-Tier Pharma Large Pharma (top 20)
Source: Ventiv Health, 2005
24
17
21
31
Major challenges for developers
Innovation Challenge: Drug Discovery is a Long, Rigorous Process
INDEFINITE
Drug Discovery Preclinical Clinical Trials FDA Review Scale-Up to Mfg.Post-MarketingSurveillance
ONE FDA-APPROVED
DRUG
0.5 – 2 YEARS6 – 7 YEARS3 – 6 YEARS
NUMBER OF VOLUNTEERS
PHASE 1 PHASE 2 PHASE 3
5250~ 5,000 – 10,000
COMPOUNDS
PR
E-D
ISC
OV
ER
Y
20–100 100–500 1,000–5,000
IND
SU
BM
ITT
ED
ND
A S
UB
MIT
TE
D
Innovation at Risk Today: US Biopharma Business Model Becoming Unstable
• Investment companies reported that through Sept 2008, biotech financing fell to $8.2 billion, 54% lower than the $17.9 billion raised in 2007.
• In late 2008, Jefferies & Co. reported that “87% of biotech companies still remain unprofitable.”
• In 2008, Pfizer pulled out of cardiovascular and other disease areas in order to stay profitable.
Innovation at Risk Today: Innovation at Risk Today: Access to New Innovation Highly Access to New Innovation Highly UncertainUncertain
Private insurers and government drive nearly all use of medicines to generics and
“preferred” brands, making it harder for new medicines to reach patients and succeed in the
marketplace
FormulariesList of covered drugs
Tiered CopaysHigher cost to patients
for brands than for generics and preferred
brands
Prior AuthorizationPhysicians required to justify
medicine’s use before it’s covered, diminishing
prescribing of such drugs
Step TherapyPatients must try and fail on alternatives before certain
medicines are covered
Financial IncentivesPayments to physicians
and/or pharmacies for high generic prescribing rate or
switching patients to preferred drugs
Government Policy Challenges
1938 1962 2009
Drug Safety Efficacy
Comparative EffectivenessCost Effectiveness
Objective Subjective
Challenges:
Legal
RegulatoryEconomic
Political
Doctors/PatientsDrugs
Governmental
Scientific
•Can value judgments be made by third parties?
“Value, like beauty,is in the eye of the beholder.”
- Twila Brase
Major Threats to Pharmaceutical Major Threats to Pharmaceutical InnovationInnovation
Major Threats to Pharmaceutical Major Threats to Pharmaceutical InnovationInnovation
• Industry productivity and output Rapidly rising R&D costs Increasing size of clinical trials Increasing regulatory pressure
• Political threat of price controls in US Rising global healthcare costs Global price disparities
• Public discontent Safety of prescription drugs Regulatory agency accountability Industry Rx marketing practices
GenzymeInnovations for unmet medical needs
• Unmet medical needs
• Novel/innovative products
• Well defined patient and physician populations
• Complex regulatory & reimbursement strategies not
• an obstacle
• Definable pathway to commercialization
• Sustainable shareholder value
Genzyme Strategic Principles for External New Product Opportunities
• Commercial Stage Product Opportunity
• Clinical Stage Product Opportunity
• Preclinical Stage Product Opportunity
• Preclinical Stage Research Opportunity
• Diagnostic Test Opportunity
What are We Looking For?
• New product within pre-existing Genzyme markets
– Additional product for existing call-point
– Expand geographic coverage
– Expand indications
– Improve product penetration
• White space expansion
– First entry into new commercial space
– Backfill pipeline
Commercial Stage Product Opportunity
– Area(s) of common scientific interest
– Complementary skills, reagents or experience
– Often identified by Science staff
Preclinical Stage Research Opportunity
Genzyme External Opportunity Evaluation: FAQ
• What kind of deals does Genzyme do?
• Broad spectrum of deals :
–Acquisition
–Joint Ventures
–Product/Opportunity in-license
–Sponsored Research Agreements
–Joint Research Programs
ProductFocused
The search process is not bound by : $ , country , partners
Competitors :
Partners :
Every General Manager act as :
Genzyme Focus Areas
• Established focus areas (products/services)– Lysosomal Storage Diseases / Genetic Diseases– Renal– Transplantation– Endocrinology– Oncology– Orthopaedics– Diagnostics
• Emerging focus areas– Cardiovascular disease– Autoimmune diseases– Neurological diseases
• White space opportunities
All is Clear ?Any Questions?